iFAST is a startup. Brouky records 1 investor associated with the company.
iFAST develops a rapid antimicrobial susceptibility testing (AST) diagnostic that reduces time-to-result from over 48 hours to approximately 3 hours, aiming to address antimicrobial resistance.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.